Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development: Proceedings of the Twenty-Second Annual Cancer Symposium Detroit, Michigan, USA — April 26–28, 1990Frederick A. Valeriote, Thomas H. Corbett, Laurence H. Baker Springer Science & Business Media, 6 груд. 2012 р. - 409 стор. The focus of the 22nd Annual Detroit Cancer Symposium was the presentation and discussion of cytotoxic agents, with a significant portion of the symposium including the exciting frontiers of drug discovery being explored by the National Cooperative Drug Discovery Groups (NCDDG) Program. The symposium brought together a large number of investigators from government, universities and pharmaceutical companies involved in the discovery and development of new anticancer agents. Exciting new leads were presented and the status of others presently under development was discussed. Of particular significance has been the initiation of renewed efforts in the area of natural product drug discovery, where the discovery of new cytotoxics is very promising at the moment. A number of major changes have occurred during the last decade in research on drug discovery of cytotoxic agents. Critical reviews of a number of the models and concepts underlying drug discovery represented a continuous thread throughout the meeting, being constantly discussed in terms of their advantages, disadvantages and capabilities of discovering solid tumor active anticancer agents. A recent development which is to be much applauded and which portends to great discoveries is the new relationship formed between Government, University of Industry. The NCDDG mechanism which stimulates this interaction is an inexpensive manner to greatly magnify the drug discovery and development effort nationally. Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development represents a forum which will become the major mode for bringing together these three different components in the equation to regularly discuss new results and ideas. |
Зміст
11 | |
DISCOVERY OF SOLID TUMOR ACTIVE AGENTS USING | 35 |
THYMIDYLATE SYNTHASE INHIBITION OF MODIFIED | 88 |
35 | 98 |
DNAMINOR GROOVE BINDING ANTICANCER AGENTS | 105 |
7 | 129 |
DISCOVERY | 148 |
9 | 170 |
11 | 205 |
EXTRACHROMOSOMAL DNA AS A TARGET FOR DRUG | 225 |
AGENTDIRECTED PRECLINICAL TOXICOLOGY FOR | 247 |
ANTIGROWTH FACTOR RECEPTOR ANTIBODIES | 303 |
19 | 319 |
20 | 331 |
ESPERAMICIN A₁ BMY28175 | 345 |
MODIFIED 2TUMOR L1210 COLON 38 ASSAY | 359 |
Інші видання - Показати все
Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and ... Frederick A. Valeriote,Thomas H. Corbett,Laurence H. Baker Обмежений попередній перегляд - 1992 |
Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and ... Frederick A. Valeriote,Thomas H. Corbett,Laurence H. Baker Попередній перегляд недоступний - 1992 |
Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and ... Frederick A. Valeriote,Thomas H. Corbett,Laurence H. Baker Попередній перегляд недоступний - 2012 |
Загальні терміни та фрази
acid administration Adriamycin agar agents AMAPS analogs anti-Tf receptor MAbs antibiotic anticancer drugs antitumor activity assay binding Biochem Biol bolus bolus FUra brequinar sodium Cancer Res carcinoma cell growth cell kill cell lung cellular Chem chemical cisplatin clinical trials colon 38 compounds concentration crisnatol cytotoxic DHO-DHase diphtheria toxin disk dosage drug discovery effects efficacy EGF receptor enzyme episomes esperamicin evaluation Figure fusion toxin gene growth factor receptor human tumor cell IL-2 receptor implanted infusion inhibitors injection interaction interleukin-2 kinase L1210 leukemia leukemia maytansine mean graph mechanism melanoma mg/kg mg/M²/day mice molecular molecule monoclonal antibodies mouse murine Natl oligomers oncogene patients Phase piercidin plates polyamine preclinical Proc produced protein PVI-FUra pyrimidine quinazoline radiosensitizer response schedule screening selectivity sensitive solid tumor structure studies subpanels synthesis Table target Taxotere tested Tf receptor therapeutic therapy tion toxicity treatment vitro vivo xenografts